MONARCH 3: Interim overall survival (OS) results of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+, HER2-advanced breast cancer (ABC)

被引：69

作者：

Goetz, M. P. ^{[1
]}

Toi, M. ^{[2
]}

Huober, J. ^{[3
]}

Sohn, J. ^{[4
]}

Tredan, O. ^{[5
]}

Park, I. H. ^{[6
]}

Campone, M. ^{[7
]}

Chen, S. C. ^{[8
]}

Sanchez, L. M. Manso ^{[9
]}

Paluch-Shimon, S. ^{[10
]}

van Hal, G. ^{[11
]}

Shahir, A. ^{[11
]}

Iwata, H. ^{[12
]}

Johnston, S. ^{[13
]}

机构：

[1] Mayo Clin, Dept Oncol, Rochester, MN USA

[2] Kyoto Univ Hosp, Breast Unit Dept, Kyoto, Japan

[3] Kantonsspital St Gallen, Dept Interdisciplinary Med Serv, St Gallen, Switzerland

[4] Yonsei Univ, Dept Med Oncol, Seoul, South Korea

[5] Ctr Leon Berard, Med Oncol, Lyon, France

[6] Korea Univ Coll Med, Hemato Oncol, Seoul, South Korea

[7] ICO Inst Cancerol Ouest Rene Gauducheau, Dept Med Oncol, St Herblain, France

[8] Taipei Chang Gung Mem Hosp, Chang Gung Med Fdn, Gen Surg, Taipei, Taiwan

[9] Hosp Univ 12 Octubre, Dept Med Oncol, Madrid, Spain

[10] Hadassah Univ Hosp Ein Kerem, Oncol, Jerusalem, Israel

[11] Eli Lilly & Co, Oncol, Indianapolis, IN USA

[12] Aichi Canc Ctr Hosp, Breast Oncol Dept, Nagoya, Japan

[13] Royal Marsden Hosp, Med Oncol, London, England

来源：

关键词：

D O I：

10.1016/j.annonc.2022.08.009

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA15

引用

页码：S1384 / S1384

页数：1